Distant metastasis of salivary gland cancer: Incidence, management, and outcomes

Abstract

BACKGROUND: Distant metastases (DMs) are the primary cause of treatment failure in patients with salivary gland carcinoma. There is no consensus on the standard treatment. METHODS: Patients with DMs were identified from an institutional database of 884 patients with salivary gland cancer who underwent resection of the primary tumor between 1985 and 2015. Survival outcomes for patients with DMs were determined with the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify factors associated with DM. RESULTS: Of the 884 patients identified, 137 (15%) developed DMs during follow-up. Most of the primary tumors (n = 77 [56%]) were located in a major salivary gland. At clinical presentation, 53% of the tumors were classified as T3 or T4, and 32% had clinical node metastases. The median time to DM was 20.3 months. The factors associated with shorter distant recurrence-free survival were male sex, high-risk tumor histology, and advanced pathological T and N classifications. Patients with bone metastases had a lower survival rate than patients with lung metastases. The total number of DMs in a patient was inversely associated with survival. Patients who underwent surgical resection of DMs had a significantly higher 5-year rate of metastatic disease-specific survival than patients who underwent observation or nonsurgical treatment (44%, 29%, and 19%, respectively; P = .003). CONCLUSIONS: In patients with DMs of salivary gland carcinoma, survival is negatively associated with high-grade histology, bone DMs, and the total number of DMs. Metastasectomy can help to lengthen disease-free survival. Cancer 2020;126:2153-2162.

Clinical Characteristics and Prognosis of Patients With Pulmonary Mucoepidermoid Carcinoma: A SEER-Based Analysis

“…Surgical resection treatment was the optimal treatment option for PMEC patients. This finding is in agreement with the previous research results ( 26 – 28 ). Furthermore, we further analyzed the impact of surgical options on survival.…”

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

“…Numerous clinical trials of cytotoxic chemotherapies have been conducted in patients with recurrent and/or metastatic (R/M) SGC 3,4 and several potential targets for systemic therapy have been reported [5][6][7][8][9][10][11][12][13][14][15][16][17] ; however, there were no randomised controlled trials 3,4 . Moreover, unlike lung metastasis of adenoid cystic carcinoma (AdCC), majority of which show indolent growth 3,18,19 , the progression of salivary duct carcinoma (SDC) and adenocarcinoma, not otherwise specified (NOS) is aggressive 3,20,21 . Hence, there is a need for systemic therapeutic strategies based on the histological characteristics for SGC.…”

Neue Therapieansätze für Speicheldrüsenmalignome

“…Betroffene Patienten haben ein 5-Jahres-Gesamtüberleben von lediglich 20 % [12]. Zudem zeigen adenoidzystische Karzinome ein schlechtes Ansprechen auf konventionelle zytostatische Therapien [27,28] Das Mukoepidermoidkarzinom ist die häufigste Entität maligner Speicheldrüsenkarzinome [3,30]. Bei ca.…”